Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25


Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction.

Hernández-Díaz S, Varas-Lorenzo C, García Rodríguez LA.

Basic Clin Pharmacol Toxicol. 2006 Mar;98(3):266-74.


Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.

Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E; CLARITY-TIMI 28 Investigators.

N Engl J Med. 2005 Mar 24;352(12):1179-89. Epub 2005 Mar 9.


Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.

Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM.

N Engl J Med. 2005 Mar 17;352(11):1081-91. Epub 2005 Feb 15.


Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.

Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M; Adenoma Prevention with Celecoxib (APC) Study Investigators.

N Engl J Med. 2005 Mar 17;352(11):1071-80. Epub 2005 Feb 15.


Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators.

N Engl J Med. 2005 Mar 17;352(11):1092-102. Epub 2005 Feb 15. Erratum in: N Engl J Med. 2006 Jul 13;355(2):221.


Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding.

Chan FK, Ching JY, Hung LC, Wong VW, Leung VK, Kung NN, Hui AJ, Wu JC, Leung WK, Lee VW, Lee KK, Lee YT, Lau JY, To KF, Chan HL, Chung SC, Sung JJ.

N Engl J Med. 2005 Jan 20;352(3):238-44.


Current approaches to prevent NSAID-induced gastropathy--COX selectivity and beyond.

Becker JC, Domschke W, Pohle T.

Br J Clin Pharmacol. 2004 Dec;58(6):587-600. Review.


Risks of clinically significant upper gastrointestinal events with etodolac and naproxen: a historical cohort analysis.

Weideman RA, Kelly KC, Kazi S, Cung A, Roberts KW, Smith HJ, Sarosi GA, Little BB, Cryer B.

Gastroenterology. 2004 Nov;127(5):1322-8.


Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.

Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona A, Hawkey CJ; TARGET Study Group.

Lancet. 2004 Aug 21-27;364(9435):665-74.


Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents.

Laporte JR, Ibáñez L, Vidal X, Vendrell L, Leone R.

Drug Saf. 2004;27(6):411-20.


COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study.

Nørgård B, Pedersen L, Johnsen SP, Tarone RE, McLaughlin JK, Friis S, Sørensen HT.

Aliment Pharmacol Ther. 2004 Apr 1;19(7):817-25.


Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding.

Stack WA, Atherton JC, Hawkey GM, Logan RF, Hawkey CJ.

Aliment Pharmacol Ther. 2002 Mar;16(3):497-506.


Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ; VIGOR Study Group.

N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528.


Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding.

Lanas A, Bajador E, Serrano P, Fuentes J, Carreño S, Guardia J, Sanz M, Montoro M, Sáinz R.

N Engl J Med. 2000 Sep 21;343(12):834-9.


Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS.

JAMA. 2000 Sep 13;284(10):1247-55.


Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2.

Brooks P, Emery P, Evans JF, Fenner H, Hawkey CJ, Patrono C, Smolen J, Breedveld F, Day R, Dougados M, Ehrich EW, Gijon-Baños J, Kvien TK, Van Rijswijk MH, Warner T, Zeidler H.

Rheumatology (Oxford). 1999 Aug;38(8):779-88.


Supplemental Content

Support Center